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ABSTRACT
Glioblastoma (GBM) stem cells (GSCs) reside in both hypoxic and vascular
microenvironments within tumors. The molecular mechanisms that allow GSCs to
occupy such contrasting niches are not understood. We used patient-derived GBM
cultures to identify GSC subtypes with differential activation of Notch signaling,
which co-exist in tumors but occupy distinct niches and match their metabolism
accordingly. Multipotent GSCs with Notch pathway activation reside in perivascular
niches, and are unable to entrain anaerobic glycolysis during hypoxia. In contrast,
most CD133-expressing GSCs do not depend on canonical Notch signaling, populate
tumors regardless of local vascularity and selectively utilize anaerobic glycolysis
to expand in hypoxia. Ectopic activation of Notch signaling in CD133-expressing
GSCs is sufficient to suppress anaerobic glycolysis and resistance to hypoxia. These
findings demonstrate a novel role for Notch signaling in regulating GSC metabolism
and suggest intratumoral GSC heterogeneity ensures metabolic adaptations to support
tumor growth in diverse tumor microenvironments.

INTRODUCTION

brain malignancy (http://www.cbtrus.org). Despite
surgery and chemoradiotherapy, prognosis remains poor
[1-3]. GBM growth is maintained by a dynamic cellular
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hierarchy dominated by GBM stem cells (GSCs) [4-10].
Due to their inherent resistance to current therapies, GSCs
represent crucial therapeutic targets [9-11].
A major challenge in GBM is its inter- [12, 13] and
intra-tumoral [14-16] heterogeneity. In particular, GBM’s
microenvironmental heterogeneity is highlighted by areas
of microvascular proliferation interspersed with hypoxic
regions of pseudopalisading necrosis (PPN) [17]. Both
microenvironments harbor GSCs [18-27]. The differences
in vascularity and oxygen tension between these niches
suggest distinct molecular mechanisms regulating GSC
self-renewal and metabolism. However, these mechanisms
are not understood.
The Notch signaling pathway, critical for neural
stem cell (NSC) self-renewal and differentiation [2831], also regulates GSC self-renewal, tumorigenicity,
radioresistance and differentiation into vascular lineages
[6, 32-36]. Upon binding the Delta or Jagged families of
ligands, the Notch receptor is cleaved by γ-secretase [31].
Cleaved Notch intracellular domain (NICD) translocates
to the nucleus, where it forms a complex with RBPJ
and MAML to activate transcription of HES and HEY
genes, which maintain multipotency [29-31]. Tumor
endothelium provides Notch ligands, which support GSC
self-renewal in the perivascular niche [18, 37-40], similar
to NSCs [41-43]. In light of the theory that avascular
microenvironments lacking endothelium-derived Notch
ligands also harbor GSCs, we hypothesized that the Notch
pathway is required for self-renewal of perivascular GSCs,
but not GSCs located in hypoxic niches.
Here, we show that nuclear NICD is found in tumor
cells within perivascular but not hypoxic regions of human
GBM. In contrast, CD133 (PROM1), a transmembrane
glycoprotein that marks GSCs [4, 9, 19, 20, 44, 45],
is expressed primarily in areas of PPN and less so in
perivascular niches. Prospective isolation of cells with
active Notch signaling (Notchhi) using patient-derived
cultures bearing a fluorescent Notch reporter demonstrates
only partial overlap and extensive segregation of Notchhi
cells and CD133-expressing (CD133hi) GSC populations
in vitro and in vivo in intracranial xenograft tumors..
These cell populations occupy discreet niches in tumor
xenografts, similar to patient tumors, and demonstrate
distinct metabolic, transcriptional and differentiation
profiles. Notchhi cells not only reside in perivascular
niches, but also contribute pericyte lineages to their
vascular microenvironment via a broader multipotency
profile compared to CD133hi cells. We demonstrate that
Notchhi cells are vulnerable to hypoxia due to inability to
entrain anaerobic glycolysis, as opposed to CD133hi cells.
Ectopic activation of Notch signaling in CD133hi cells is
sufficient to confer vulnerability to hypoxia and reprogram
metabolism away from anaerobic glycolysis.
Our findings indicate Notch signaling is
heterogeneously activated within the GSC population
and regulates metabolic adaptations to the local
www.impactjournals.com/oncotarget

microenvironment. Our model provides a mechanistic
understanding of intratumoral GSC heterogeneity, as
well as a platform for elucidating microenvironmental
regulation of stem cell behavior.

RESULTS
Notch signaling is activated in perivascular niches
but not hypoxic areas of human GBM
To determine the spatial profile of Notch pathway
activation in GBM, we stained 9 formalin-fixed paraffinembedded (FFPE) human GBM biospecimens for Notch1
Intracellular Domain (NICD1) (Supplementary Table 1).
All 9 biospecimens were classified as GBM based on H&E
staining (Figure 1ai). Nuclear NICD1 was detected in
perivascular areas (Figure 1aii, top panel), but was absent
in regions of PPN (4/9 biospecimens with areas of PPN;
5 biospecimens did not show PPN) (Figure 1aii, bottom
panel; Supplementary Figure 1a).
Immunofluorescence analysis indicated CD133
localizes to both perivascular and avascular areas in
human GBM, as in previous reports [19, 20] (Figure
1aiii). Unlike NICD1, CD133 was consistently found in
PPN areas in each biospecimen (Supplementary Figure
1b). Given that Notch signaling and CD133 expression
showed differential localization and both have been linked
with GSCs, we hypothesized expression of these markers
identifies distinct GSC populations.

Prospective isolation of tumor cells with Notch
pathway activation
In order to further characterize cell populations
identified by activation of Notch signaling and expression
of CD133, we used patient-derived tumorsphere
cultures (GBML8, 20, 33, 61) [7, 44, 46, 47]. Molecular
subtyping of parental biospecimens was performed
with DNA methylation profiling (Illumina 450K arrays)
(Supplementary Figure 2ai) [47, 48]. The analysis
classified GBML8 in the mesenchymal, and GBML20,
GBML33 and GBML61 in the RTK1 (proneural)
subtypes (Supplementary Figure 2b). Parental tumors had
several molecular hallmarks of primary GBM, including
trisomy 7 and loss of PTEN, CDKN2A, NF1 and RB1.
Tumors showed microvascular proliferation and PPN.
In addition, tumors were negative for IDH1/2 mutations
(Supplementary Figure 2ai-2aiii).
In these patient-derived cultures, we prospectively
isolated cells with active canonical Notch signaling using
a lentiviral reporter (NotchLenti) that expresses copGFP,
a green fluorescent protein with short half-life (~2 hours)
[49] that allows dynamic visualization of cells upon
activation of the Notch pathway (Figure 1b) [29, 30]. The
64933
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Figure 1: Notch activation and CD133 cell surface expression show differential intratumoral localization in human
GBM. a., i. H&E reveals areas of microvascular proliferation (top panel) and PPN (bottom panel) within the same human GBM

biospecimen. a., ii. Nuclear NICD1 immunoreactivity is seen in perivascular areas but not in PPN regions. a., iii. In contrast, CD133
immunoreactivity is seen in both microenvironments. b. Schematic of the lentiviral vector used to monitor Notch pathway activation. The
20 bp-long Notch response element contains a consensus GTGGGAA site found in Notch transcriptional targets. c. Schematic depicting the
approach for obtaining patient-derived primary tumorsphere cultures and orthotopic tumor xenografts after transduction with NotchLenti.
Scattered Notch-activated (GFP+) cells (arrowheads) were observed in tumorspheres in vitro. d. Flow cytometry histograms of GBM lines
show gradients of (i) increased GFP fluorescence after transduction with NotchLenti and (ii) CD133 immunoreactivity after incubation with
anti-CD133 antibody (n = 3 primary cultures). e. Immunofluorescent analysis of xenograft tumors generated by GBML8 cells modified
with NotchLenti reveals perivascular GFP staining for Notch activation. f. Quantification of the distance of GFP+ or CD133-expressing
cells from the vasculature (i) in xenograft tumors generated with 2 patient-derived cultures already modified with NotchLenti shows that
GFP+ cells prefer a perivascular localization. (n = 3 animals for each condition, ii: GBML8: ANOVA, F(2,8) = 16.93, P < 0.003 and iii:
GBML20: ANOVA, F(2,8) = 6.049, P < 0.03). H&E: hematoxylin and eosin; N: necrosis; BV: Blood vessel; CMV: Cytomegalovirus; GFP:
Green Fluorescence Protein; CD105: Endoglin; DAPI: nuclear counter stain; ns: not significant.
www.impactjournals.com/oncotarget
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reporter consists of 4 tandem Notch response elements
attached to a minimal CMV promoter. Each response
element contains a consensus GTGGGAA motif found in
the promoters of the NICD target genes HES1 and HES5
(Figure 1b). After treatment with 1 μg/ml puromycin to
select for transduced cells, we observed scattered GFP+
cells in our tumorsphere cultures (Figure 1c). These
cultures were used for further characterization (Figure 1c).
Flow cytometric analysis of 3 primary cultures transduced
with NotchLenti (GBML8, GBML20, GBML33) showed
a gradient of GFP signal (Figure 1d). This flow cytometric
profile was similar to the one we obtained with a HES5mCherry reporter utilizing 760 bp of the HES5 promoter

(not shown) [29]. To define cells with GFP intensities
higher than the negative control (parental cultures not
transduced with NotchLenti), we used conventional gating
with linear cutoffs in fluorescence intensity. We found that
only a small population of cells (1.80 ± 0.06%) showed
the highest activation of Notch signaling (Figure 1di).
CD133 surface expression in these primary cultures was
also represented by a gradient with variable percentages
of CD133-positive cells (35.43 ± 19.51%) (Figure 1dii).
To test the fidelity of the Notch reporter, we
examined the effects of soluble Notch ligand deltalike 4 (Dll4) or the γ-secretase inhibitor DAPT on
the abundance of GFP+ cells, using flow cytometry.

Figure 2: Segregation of Notchhi and CD133hi cell populations. a., i Flow cytometric analysis of an intracranial tumor xenograft

derived from GBML8-NotchLenti cells shows the segregation of CD133 expression (CD133hi) and Notch activation (Notchhi). a., ii Flow
cytometric analysis of cell surface CD133 and Notch activation (GFP reporter) in 3 primary cultures in vitro shows that there is only partial
overlap between the two markers. For the analysis in a., GFP gates were drawn based on parental cultures not transduced with NotchLenti,
and CD133 gates were based on control conditions without antibody (as shown in Supplementary Figure 2c). b. Experimental plan for
studying Notchhi and CD133hi cells. c. FACS-sorted CD133hi, Notchhi and DP cells were compared to DN cells for CD133 (PROM1) and
HES5 mRNA expression by qPCR. The experiment was performed on two different primary cultures transduced with NotchLenti: (i)
GBML8, and (ii) GBML20 (n = 3 FACS experiments/primary cell line, t-tests, P < 0.05). d. After FACS isolation, cells were seeded at
low density (10 cells/μl) and tumorsphere formation was analyzed 7 days after isolation. Only Notch-activated populations (Notchhi and
DP) showed decreased tumorsphere formation upon pharmacological inhibition of the Notch pathway with 10 µM DAPT in 2 cultures: (i)
GBML8: ANOVA, F(7,14) = 9.472, P < 0.0002, (ii) GBML20: ANOVA, F(1.4) = 74.98, P < 0.001) (n = 3 experiments/primary cell line). e. To
further confirm CD133hi and Notchhi cells represent distinct populations in GBM, we performed RNA-seq from FACS isolated cells from
GBML8 and GBML20. RNA sequencing revealed 420 genes that were differentially expressed in CD133hi and Notchhi GSCs compared to
DN cells (P < 0.05). f. When the RNA-seq data were analyzed for known GSC markers, CD133hi and Notchhi cells showed enrichment for
these transcripts compared to the DN population (n = 7 genes, ANOVA F(1, 6) = 7.490, P < 0.03). ns: not significant.
www.impactjournals.com/oncotarget
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We observed significant (1.9 ± 0.3-fold) upregulation
in the percentage of GFP+ cells upon Dll4 (100 ng/
ml) treatment (Supplementary Figure 2a). Conversely,
we found significant downregulation in the fraction
of GFP+ cells (0.5 ± 0.1-fold) after DAPT (10 μM)
treatment (Supplementary Figure 3a). In vitro lentiviral
overexpression of NICD1 (NICD-OE) increased the
mean intensity of GFP fluorescence in primary cultures

(Supplementary Figure 3bi) and the abundance of
GFP+ cells (Supplementary Figure 3bii). These findings
suggested that the NotchLenti construct faithfully reports
Notch pathway activation in GBM cells.
We used confocal microscopy to examine the
distribution of CD133+ and GFP+ (active Notch signaling)
cells in orthotopic tumor xenografts generated from two
primary GBM cultures (Figure 1e-1f). While GFP+ cells

Figure 3: Notchhi cells reside higher in the cellular hierarchy in vivo. a. Cells were isolated with FACS and xenograft tumors

generated were analyzed by flow cytometry and histology 6 months after injection. b., i Tumor cells were isolated from intracranial
xenografts generated either by CD133hi or Notchhi cells (GBML8) after confirmation of tumors with MRI. b., ii-iii Flow cytometric analysis
revealed that tumors initiated by CD133hi GSCs contained significantly lower numbers of Notchhi cells, whereas CD133 percentages did
not significantly change between the two different types of tumors (n = 3 animals/condition, ANOVA F(1,8) = 9.7, P < 0.01). c. Confocal
immunofluorescence analysis of tumor xenografts generated by parental (i), CD133hi (ii) and Notchhi (iii) GBML8 cells shows that tumors
generated by Notchhi GSCs more closely resemble parental tumors than CD133hi tumors (n = 3 animals/condition).
www.impactjournals.com/oncotarget
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localized to perivascular spaces, CD133+ cells showed
a diffuse distribution within tumors. Using quantitative
image analysis, we analyzed the prevalence of CD133+
and GFP+ cells in zones defined according to the distance
from the tumor endothelium (Figure 1fi). This analysis
revealed that GFP+ cells had a significantly higher
probability of residing close to endothelium than CD133+
cells, which had a more uniform spatial distribution
(GBML8 and GBML20, Figure 1fii-iii). Collectively,
these findings reproduce observations in patients’ tumors
and suggest the CD133+ and GFP+ populations are
distinct and occupy different niches.

transcript, in FACS-isolated subpopulations. We observed
significant enrichment of PROM1 transcript in CD133hi
and DP populations, and HES5 transcript in Notchhi and
DP populations, when compared to DN cells (GBML8:
Figure 2ci, GBML20: Figure 2cii), providing validation
of our experimental model. Expression of other Notch
pathway elements, including NOTCH1, NOTCH2, HES1,
HEY 1, DLL1, JAG1 and JAG2 showed no significant
changes in expression levels among the 4 subpopulations
(Supplementary Figure 4b, 4c).
We next examined the ability of these cell
populations to initiate tumorspheres in vitro and
tumor xenografts in vivo. First, we FACS-isolated the
subpopulations (CD133hi, Notchhi, DP and DN) and plated
them in limiting dilutions (10 cells/μL) to determine
sphere formation efficiency. All 4 populations showed
equivalent sphere formation ability in 2 primary cultures
tested (GBML8: Supplementary Figure 5ai, GBML20:
Supplementary Figure 5aii). There were no differences
in the size of the spheres (not shown). To test in vivo
tumorigenicity, we injected FACS-isolated cells into the
cerebrum of NOD.SCID mice (1.5 x 104 cells/animal).
We observed tumor formation in all conditions (n = 2
primary GBM cultures, Supplementary Figure 5b, 5d),
suggesting the presence of tumor-initiating cells in all
subpopulations. Notably however, while the size of
Notchhi cell-derived tumors was not different from that of
CD133hi tumors, it was significantly larger than the size
of DP and DN-derived tumors (Supplementary Figure
5c), suggesting enhanced tumorigenic potential in Notchhi
and CD133hi cells compared to DP and DN cells. CD133hi
and Notchhi cells produced tumor xenografts even when
injected at even greater dilutions (1.5 x 103 cells/animal;
Supplementary Figure 5d).
In addition, we tested the self-renewal capacity of
the distinct populations. Serial tumorsphere assay using
FACS-isolated subpopulations from GBML8 revealed
that all populations maintain their self-renewal for at
least 3 passages (Supplementary Figure 5e). To test serial
xenograft formation, we FACS-isolated subpopulations
from a xenograft tumor formed from GBML20 cells. We
observed that all of the animals injected with CD133hi and
Notchhi cells showed tumor formation, however only 1/2
animals showed tumor formation from DN cells (n = 3 for
CD133hi and Notchhi and n = 2 for DN) (Supplementary
Figure 5f). DP cells were not used for this assay. These
findings indicate that CD133hi and Notchhi cells have
enhanced and sustained tumorigenicity. Of note, the
percentage of CD133hi and Notchhi cells remained stable
over a 15-month period in vitro, indicating long-term selfrenewal (n = 3 cultures, Supplementary Figure 5g-5h).
Previous data suggested inhibition of Notch
signaling depletes CD133-expressing cells [6, 33].
However, recent reports indicated that not all CD133positive GBM cells are sensitive to γ-secretase inhibitors
[51]. To explain this controversy, we tested whether

Notch activation and CD133 surface expression
mark distinct cell populations
To test the hypothesis that cells with active Notch
signaling are distinct from CD133-expressing cells,
we performed flow cytometric analysis of NotchLentitransduced GBM tumorsphere cultures (GBML8,
GBML20 and GBML33) and tumor xenografts from
these cells. We found in vivo segregation of the CD133expressing (CD133hi) cell population (17.55 ± 2.50% of all
tumor cells) and the population of cells with active Notch
signaling (Notchhi; 3.87 ± 0.85% of all tumor cells, n =
4 mice implanted with NotchLenti-transduced GBML8
cells) (Figure 2ai). In vitro flow cytometric analysis of 3
primary cultures transduced with NotchLenti reproduced
the segregation observed between Notchhi and CD133hi
cells (Figure 2aii, Supplementary Figure 3c). There was
only partial overlap between the Notchhi and CD133hi
populations, so that only 43.64 ± 25.38% of Notchhi cells
were CD133hi. Conversely, only 2.4 ± 0.3% of CD133hi
cells were Notchhi. Supplementary Figure 3cii summarizes
the cumulative statistics of all the subpopulations
generated with respect to CD133 and Notch activation
status: CD133hi/Notchlo (CD133hi), Notchhi/CD133lo
(Notchhi), double positives (DP) and double negatives
(DN). These findings suggested partial overlap between
these two markers and largely distinct CD133hi and Notchhi
cell populations.
To validate the segregation of CD133hi and Notchhi
cell populations at the molecular level and to assess
their cellular properties, we FACS-isolated CD133hi,
Notchhi, DP and DN cells, and subjected them to further
characterization (Figure 2b). In order to ensure that our
results were not confounded by loss of the NotchLenti
reporter construct, we performed PCR for the copGFP
transgene from genomic DNA isolated from all 4 FACSsorted cell populations, which confirmed that the reporter
transgene was present in the genome of all subpopulations
(GBML8, Supplementary Figure 4a).
We performed qRT-PCR for transcripts encoding
HES5, the principal transcriptional target of the Notch
pathway in GBM [50], as well as the PROM1 (CD133)
www.impactjournals.com/oncotarget
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Figure 4: CD133hi and Notchhi GSCs have distinct angiogenic properties. a. Representative images of GBML8 xenografts show

the contrast in vascular morphology of tumors derived from Notchhi (top panel) and CD133hi (bottom panel) cells (n = 3 animals/cell type).
b. No significant change was observed in the number of vessels and average vascular area in xenografts generated by Notchhi or CD133hi
cells from cultures GBML8 and GBML20 (4 20x fields/condition, n = 3 animals/cell type, t-tests, P > 0.05). c. Notchhi-initiated tumors
contain large-caliber vessels, which are absent in CD133hi tumors (GBML8 and GBML20, n = 3 animals/cell type; Wilcoxon test, P <
0.001). d.,e. CD133hi tumors showed reduced perfusion (Evans Blue staining) and increased hypoxia (pimonidazole staining), compared to
tumors generated by Notchhi cells (representative images from GBML8 xenografts, n = 3 animals/condition). f. Tumors initiated by Notchhi
and CD133hi cells do not contain hNA+ endothelium (CD105+ cells) (representative images from GBML8 xenografts, n = 3 animals/cell
type). g. α-SMA+ pericytes envelope larger vessels in Notchhi tumors (top panel). CD133hi tumors are devoid of pericytes (representative
images from GBML8 xenografts, n = 3 animals/cell type). h. Lineage tracing in GBML8 xenografts shows GFP+ pericytes, indicating that
they are derived from Notchhi cells. The inset shows that CD105+ endothelium is GFP- (n = 3 animals). ns: not significant.
www.impactjournals.com/oncotarget
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inhibition of Notch signaling with the γ-secretase inhibitor
DAPT (10 µM) differentially impairs tumorsphere
formation in these subpopulations. Inhibition of Notch
activation selectively inhibited tumorsphere formation in
Notchhi and DP, but not CD133hi or DN, cells (GBML8:
Figure 2di, GBML20: Figure 2dii). This result suggests
tumorsphere initiation by CD133hi cells does not depend
on Notch signaling.

seq did not show any difference between the two cell types
in transcripts encoding components of the γ-secretase
complex (PSEN1, APH1, PSENEN, NCSTN) or NICD’s
nuclear binding partners RBPJ and MAML1-3. Overall,
these findings suggest that the lack of Notch pathway
activation in CD133hi cells is not due to low expression
of the basic molecular machinery required for Notch
signaling.

Notchhi and CD133hi have distinct transcriptional
profiles but overlapping GSC signatures

Notchhi GSCs have broader differentiation
potential than CD133hi GSCs

To understand the molecular etiology of biological
differences between Notchhi and CD133hi GSCs, we
performed RNA-seq on FACS-isolated cells from
GBML8 and GBML20. We identified 420 genes that were
differentially expressed in Notchhi and CD133hi GSCs
relative to DN cells (P < 0.05; Figure 2e, Supplementary
Tables 2-7). Supervised hierarchical clustering based on
these 420 genes (Supplementary Figure 6a) revealed cells
of the same GSC subtype from different cultures clustered
together, suggesting preserved transcriptional signatures of
these subtypes across tumors. Unsupervised hierarchical
clustering using the entire transcriptome produced
similar results (Supplementary Figure 6b). Furthermore,
Notchhi and CD133hi cells clustered more closely to
each other than to DN cells, possibly due to shared GSC
transcripts underrepresented in DN cells. Indeed, when
we interrogated RNA-seq data for transcripts associated
with GSCs such as NES, SOX2, BMI1, POU5F1, CXCR4,
EZH2 and MET [5, 52], we found CD133hi and Notchhi
cells upregulate this gene network relative to the DN
population (Figure 2f). These findings suggest CD133hi
and Notchhi possess stem-like properties but differ in other
aspects of their biology.
We next tested whether molecular signatures of
parental tumors, as defined by TCGA data analysis [12],
were detected in the 4 cell populations (CD133hi, Notchhi,
DP and DN). Supervised hierarchical clustering with 448
genes used to subtype TCGA biospecimens in Verhaak
et al. [12] (Supplementary Figure 6c) validated that the
TCGA gene expression signature of parental tumors
is preserved within the 4 subpopulations of each tumor
(Supplementary Figure 6d). This finding suggested that
GSC subtypes did not represent genomically distinct
subclones within each tumor, but rather functionally
specialized subpopulations. Furthermore, it supports the
hypothesis that within any given GBM tumor, regardless
of its TCGA molecular subgroup, there exist GSC
subtypes with defined and differentially regulated gene
networks.
As shown in Supplementary Figure 4b, 4c, CD133hi
and Notchhi cells express similar levels of NOTCH1 and
NOTCH2 transcripts using qRT-PCR assays. This finding
was reproduced with RNA-seq data. Furthermore, RNA-

To test the cells’ differentiation potential, we
examined the progeny of the 4 FACS-sorted populations
7 days after isolation (GBML8 and GBML20,
Supplementary Figure 6a-6c). While populations with
active Notch signaling (Notchhi and DP) gave rise to
both Notchhi and Notchlo populations in vitro, CD133hi
cells were only able to differentiate into Notchlo
progeny (CD133hi and DN cells). DN cells generated
CD133hi lineages but failed to produce Notchhi progeny
(Supplementary Figure 7a-7c). These results suggest that
Notchhi cells have broader differentiation potential than
CD133hi cells, which show a restricted differentiation
program that excludes lineages with active Notch
signaling in vitro.
To identify progeny of CD133hi and Notchhi GSCs
in vivo, we injected FACS-sorted GBML8 cells into
mouse brains and analyzed tumor xenografts with flow
cytometry 6 months later (Figure 3a). After confirmation
of tumors with MRI (Figure 3bi), we observed that tumors
initiated by Notchhi cells contained all lineages, while
tumors initiated by CD133hi GSCs were inefficient in
generating Notchhi cells. The abundance of CD133hi cells
in the two types of tumor was not different (Figure 3bii3biii). These findings indicated broader differentiation
potential in Notchhi cells and suggested the Notchhi to
CD133hi differentiation program is tightly regulated and
predominantly unidirectional.
To test the hypothesis that Notchhi cells reside higher
than CD133hi cells in GBM’s cellular hierarchy by virtue
of their broader differentiation potential, we examined
the histology of tumor xenografts obtained by either cell
type and compared them to parental tumors derived from
unsorted cultures (GBML8, Figure 3ci-3ciii). Tumors
generated by Notchhi GSCs (Figure 3ciii) showed elaborate
vascular trees, similar to xenografts initiated by injection
of parental cultures (Figure 3ci). In contrast, tumors
initiated by CD133hi gave rise to a rather monotonous
histology, characterized by a uniform network of small
vessels (Figure 3cii). This finding supported the hypothesis
that Notchhi GSCs have a broader differentiation potential
than CD133hi GSCs.

www.impactjournals.com/oncotarget
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Notchhi and CD133hi cells differ in their angiogenic
potential

were devoid of large-diameter vessels and contained a
uniform network of smaller vessels (GBML8: Figure
4a, GBML20: Supplementary Figure 8a). Although the
number of vessels and cumulative vascular area did not
differ between the two conditions (Figure 4b), a dot plot
of the area of individual vessels demonstrated a clear
difference in size distribution (Figure 4c).

The vascular phenotype of the xenografts initiated
by Notchhi and CD133hi cells was distinct. In Notchhiderived tumors, we observed a combination of large and
small diameter vessels, whereas CD133hi-initiated tumors

Figure 5: CD133hi GSCs selectively utilize anaerobic glycolysis. a. GSEA analysis of transcriptomes of CD133hi and Notchhi

cells revealed enrichment of hypoxia-responsive genes in CD133hi GSCs. b. Heatmap showing differentially expressed genes between
CD133hi and Notchhi cells from the same gene set as in (a). c. Fold enrichment of critical hypoxia-induced genes in the CD133hi population.
d. Schematic representation of these genes in the glycolytic and oxidative phosphorylation pathways. e. Western blotting for HIF1α shows
increased protein levels after 24 hours of hypoxia in 3 different GBM cultures. f. CD133hi GSCs had higher total lactate levels than Notchhi
GSCs in normoxic conditions (n = 3 experiments/primary cell line, t-tests, P < 0.04). g. CD133hi cells had significantly lower intracellular
pH compared to Notchhi cells in normoxia (GBML8, t-test, P < 10-12). h. After 24 hours of hypoxia, CD133hi cells were able to further
increase lactate production compared to Notchhi cells (n = 3 experiments, GBML8: t-test, P < 0.05, GBML20: t-test, P < 0.03). NES:
normalized enrichment score; ETC: electron transport chain.
www.impactjournals.com/oncotarget
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We then tested whether the differences in the
morphology of the tumor vasculature correlated with
changes in tissue oxygenation. Immunofluorescence
analysis revealed that tumors initiated by CD133hi cells,
but not Notchhi cells, expressed the hypoxia marker
Carbonic Anhydrase 9 (CAIX) (Supplementary Figure 8b)
[53]. We observed that, when animals were injected with
pimonidazole i.p and Evans Blue i.v. before sacrificing,
to analyze vascular perfusion and the extent of hypoxia
in these tumors [47, 54], Notchhi-initiated tumors showed
elevated perfusion, while CD133hi-initiated tumors
showed less perfusion and increased hypoxia (Figure 4d,
4e). Collectively, these findings indicate that CD133hi
cells give rise to hypo-perfusing and hypoxic tumors, in
contrast to Notchhi-initiated tumors.
To understand the differences in vascular
morphology, we analyzed the extent of pericytic and

endothelial differentiation, since previous reports indicated
GSCs generate endothelial and pericytic lineages [32, 34,
35]. Using confocal microscopy and immunostaining for
human nuclear antigen (hNA) and CD105, we were unable
to observe tumor-derived endothelial cells in either Notchhi
or CD133hi tumors (Figure 4f). This finding suggested that
the distinct angiogenic profiles of Notchhi and CD133hi
GSCs are unlikely to be due to differences in endothelial
differentiation.
The importance of Notch signaling in the generation
of vascular pericytes has been previously demonstrated in
GBM [32, 55]. To test whether Notchhi GSCs differentiate
into pericytes, we compared tumor xenografts initiated by
Notchhi and CD133hi GSCs for pericyte immunoreactivity.
We found pericytes, identified by α-smooth muscle actin
(α-SMA) staining, only in Notchhi tumors, where they
surrounded larger-caliber vessels (Figure 4g, top panel).

Figure 6: CD133hi GSCs expand in hypoxic conditions at the expense of Notchhi GSCs. a., b. Flow cytometry shows increased

abundance of CD133hi cells after 24 hours of hypoxia in 2 of 3 cultures (GBML8 and GBML33: t-test, P < 0.02). c. The abundance of
Notchhi GSCs significantly decreases in the same conditions (t-test, P < 0.02, n = 3 primary cultures). d. Percent of cells in apoptosis
analyzed by TUNEL assay: (i) GBML8: ANOVA, F(1,8) = 5.57, P < 0.05; (ii) GBML20: ANOVA, F(1,8) = 10.79, P < 0.01. e. Percent Ki67+
cells in CD133hi and Notchhi GSCs from two different GBM cultures after 24 hours of hypoxia: (i) GBML8: ANOVA, F(1,8) = 0.047, P >
0.05; (ii) GBML20: ANOVA, F(1,8) = 1.9, P > 0.05). f. FACS-isolated CD133hi and Notchhi cells were allowed to form tumorspheres after
24 hours of hypoxia. Tumorsphere formation was analyzed 7 days later. Notchhi GSCs showed a significant reduction in their tumorsphere
formation ability after hypoxia, whereas no significant change was observed in CD133hi GSCs: (i) GBML8: ANOVA, F(1,8) = 20.27, P <
0.002; (ii) GBML20: ANOVA, F(1,8) = 56.10, P < 0.018.
www.impactjournals.com/oncotarget
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We observed no pericyte staining in CD133hi tumors
(Figure 4g, bottom panel). Quantitatively, 49.11 ± 6.56%
of α-SMA+ pericytes in Notchhi tumors (GBML8) were
tumor-derived, as determined by their co-staining for
hNA, similar to ratios in previous literature [32]. These
findings suggested that Notchhi GSCs may generate
pericyte lineages in vivo, which, correlates with formation
of large-caliber tumor vessels.
To test the hypothesis that pericytes represent
progeny of Notchhi GSCs, we used a tamoxifen-inducible
lineage tracing system (NotchLineage) in GBML8,
where CreERT2 expression is driven by the same Notchresponsive promoter we used for our NotchLenti reporter
constructs (Supplementary Figure 8ci) [56]. In this
system, induction with tamoxifen causes CreERT2, which
is specifically expressed in Notchhi GSCs, to catalyze
recombination of the reporter construct, leading to deletion
of DsRed and expression of GFP in progeny of Notchhi
GSCs. One month after tamoxifen induction, we found
clones of GFP+ cells within DsRed+ tumor xenografts
(Supplementary Figure 8cii). Confocal microscopic
analysis of GFP+ cells indicated that the pericyte marker
α-SMA overlapped with GFP expression, whereas
endothelial cells were GFP- (Figure 4h).
These results suggest Notchhi cells are multipotent
and give rise to tumor pericytes, as well as CD133hi
lineages. In contrast, CD133hi cells have a restricted
differentiation program and do not generate Notchhi cells
or pericytes. Tumors initiated by CD133hi cells do not
exhibit the complex vascular pattern that characterizes
parental and Notchhi GSC-derived tumors. The pericytic
transdifferentiation of the Notchhi cells correlates with
increased tumor vascularity, perfusion and oxygenation,
consistent with previous reports [55].

(Supplementary Table S9) with GSEA also showed
enrichment of hypoxia-related gene sets (Supplementary
Table 10a, 10b). Furthermore, analysis of these
differentially expressed genes with DAVID [62] revealed
that 7 out of the top 10 gene ontology (GO) terms were
related to glycolysis and cellular metabolism (P < 0.01,
Table S8b). These genes were differentially expressed
despite CD133hi and Notchhi cells having been cultured
under identical normoxic (20% O2) conditions prior to
RNA isolation.
The localization of CD133hi cells in hypoxic
microenvironments, increased hypoxia and decreased
perfusion in CD133hi-initiated tumors, and the upregulation
of a hypoxic transcriptional profile suggested that CD133hi
cells preferentially utilize anaerobic glycolysis (Figure
5d). To test this hypothesis, we measured lactate levels
in FACS-isolated CD133hi and Notchhi cells in normoxic
vs. hypoxic conditions. We used western blotting against
HIF1α to show stabilization of the protein upon hypoxia,
confirming that the low oxygen treatment was effective
(Figure 5e). In normoxia, CD133hi cells had 27.5 ± 7.6%
higher lactate levels when compared to Notchhi cells
(Figure 5f). CD133hi cells also showed significantly lower
intracellular pH than Notchhi cells [63], consistent with
acidification related to lactate production (Figure 5g).
When we subjected CD133hi and Notchhi cells to hypoxia
(1% O2) for 24 hours, CD133hi cells specifically turned on
anaerobic glycolysis even more, manifested as increased
lactate levels, as opposed to Notchhi cells, which failed to
do so (Figure 5h).
To test whether the ability of CD133hi cells to utilize
anaerobic glycolysis bestowed upon them a selective
growth advantage at the expense of Notchhi cells, we
subjected primary cultures modified with the NotchLenti
reporter to hypoxia for 24 hours. We observed that the
percentage of CD133hi cells increased significantly in 2/3
cultures (Figure 6a,b), consistent with prior observations
[24]. GBML20, which did not show a significant increase,
already had very high levels of CD133hi cells ( > 80%;
Figure 6a, 6b). Conversely, Notchhi percentages were
significantly lower in all samples after 24 hours in hypoxia
(Figure 6c). To identify the mechanism of this observation,
we interrogated the apoptotic and proliferative rates in the
FACS-isolated subpopulations upon hypoxia (Figure 6d,
6e). TUNEL assay indicated that hypoxia dramatically
increased apoptosis in Notchhi but not CD133hi cells
(Figure 6di-6dii, Supplementary Figure 9a). We did not
observe any significant change in the proliferation rate,
as assayed by Ki67 immunostaining, after 24 hours of
hypoxia (Figure 6ei-6eii, Supplementary Figure 9b).
We next tested the in vitro tumorsphere formation
ability of FACS-isolated CD133hi and Notchhi cells under
normoxia and hypoxia. CD133hi cells showed equivalent
sphere-formation efficiency in the two conditions.
However, Notchhi GSCs demonstrated a significant
reduction in tumorsphere formation in hypoxia (GBML8:

CD133hi GSCs expand in hypoxia by selective
utilization of anaerobic glycolysis
Our observations raise the possibility that CD133hi
cells and Notchhi cells may entrain distinct metabolic
adaptations to their local microenvironments. To
identify transcriptional networks unique to CD133hi and
Notchhi cells that may underlie metabolic differences,
we performed unbiased Gene Set Enrichment Analysis
(GSEA) [57] on the complete gene lists in the 2 cell types.
Gene sets upregulated by hypoxia were significantly
enriched in CD133hi cells (Figure 5a, 5b; Supplementary
Table 8). This set of genes included the key glycolytic
enzymes hexokinase 2 (HK2), phosphoglycerate kinase
(PGK1), and enolase 2 (ENO2); but also pyruvate
dehydrogenase kinase (PDK1) and NADH dehydrogenase
1 alpha subcomplex subunit 4 like 2 (NDUFA4L2),
which suppress oxidative phosphorylation (Figure 5c,
5d) [58-61]. Similarly, analysis of genes differentially
expressed between CD133hi and Notchhi cells (P < 0.1)
www.impactjournals.com/oncotarget
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Figure 6fi, GBML20: Figure 6fii). These findings suggest
that hypoxia permits tumor growth driven by CD133hi
GSCs, which are transcriptionally primed for anaerobic
glycolysis. However, Notchhi GSCs undergo apoptosis and,
therefore, cannot contribute to tumor growth in hypoxic
regions, consistent with their preferential localization to
perivascular areas.

identification of transduced cells by mCherry fluorescence
(Figure 7a). After 7 days, mCherry+ cells were FACSisolated and subjected to further characterization (Figure
7a, 7b). NICD-OE led to significant upregulation of the
Notch transcriptional target HES5 mRNA compared to
mCherry control virus (6.25 ± 0.76 -fold), confirming
ectopic activation of Notch signaling (GBML8, GBML20,
GBML61; Figure 7c). When we compared lactate levels
in cells transduced with NICD-OE vs. control cells, we
observed significant reduction under both normoxia (0.61
± 0.05 -fold of control, Figure 7d) and hypoxia (0.62 ±
0.14 -fold of control, Figure 7e).
To analyze the effects of ectopic Notch activation
on tumorsphere formation, we plated freshly isolated
mCherry+ cells in limiting dilutions (10 cells/μL),
subjected the cells to 24 hours of hypoxia and analyzed
sphere formation 7 days later. We found that NICD-OE led

Ectopic expression of NICD1 in CD133hi cells
suppresses anaerobic glycolysis and reduces
tolerance to hypoxia
To test the hypothesis that Notch signaling regulates
GBM cells’ response to hypoxia and their metabolism, we
ectopically expressed NICD1 in FACS-isolated CD133hi
cells using a lentiviral vector, NICD-OE, which allowed

Figure 7: Ectopic Notch activation reprograms metabolism. a. Schematic representation of the lentiviral constructs used for
ectopic activation of the Notch pathway (NICD-OE) or the control vector (mCherry) and the experimental plan. b. Representative FACS
plot from GBML8 cells that were infected with either NICD-OE or mCherry virus, showing transduction efficiency. c. FACS-isolated
mCherry+ cells from GBML8, GBML20 and GBML61 cultures showed increased HES5 transcript in the NICD-OE condition (n = 3
primary cultures, t-test, P < 0.02). d., e. Lactate level measurements in FACS-isolated mCherry+ cells after 24 hours of (d). normoxia or (e)
hypoxia. NICD-OE led to significant downregulation in lactate levels in 3 primary cultures: (d) t-test, P < 0.001; (e) t-test, P < 0.05). (f-g)
mCherry+ cells from GBML8 and GBML20 cells transduced with NICD-OE or mCherry virus were subjected to tumorsphere formation
assay under normoxia or hypoxia. Ectopic Notch activation led to reduced tumorsphere formation under hypoxic conditions, whereas
mCherry control did not show any change (n = 3/condition): f. GBML8: ANOVA, F(3,8) = 6.543, P < 0.05; (g) GBML20: ANOVA, F(3,12) =
8.256, P < 0.01. ns: not significant.
www.impactjournals.com/oncotarget
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to a significant reduction in sphere formation in hypoxia
compared to the mCherry control virus (GBML8 and
GBML20: Figure 7f, 7g). These assays reproduced the
phenotype seen with native CD133hi and Notchhi GSCs
and suggested that ectopic activation of Notch signaling
is sufficient to reprogram the metabolic profile of CD133hi
cells and suppress their tolerance to hypoxia.

intratumoral heterogeneity within GBM’s stem cell
population. We discovered that activation of Notch
signaling and CD133 (PROM1) cell surface expression,
two well-characterized GSC markers, demonstrate only
partial overlap (Notchhi/CD133hi or DP cells). Notchhi/
CD133lo (Notchhi) and CD133hi/Notchlo (CD133hi) cells,
the non-overlapping cell populations, show profound
functional differences reflected in their niches, metabolism
and differentiation profiles (Figure 8). We propose that this
heterogeneity allows GSCs to support tumor growth in a
wide spectrum of tumor microenvironments. Our results
are reproducible across GBM tumors with a wild-type
IDH background, which represent the majority of adult
GBM [12].

DISCUSSION
Inter- and intra-tumoral heterogeneity in GBM
represent major obstacles to therapy [12, 14-16]. Here,
we provide a novel model for functional and metabolic

Figure 8: Schematic summarizing the role of distinct GSCs in tumor progression.
www.impactjournals.com/oncotarget

64944

Oncotarget

The tumor microenvironment in GBM is highly
variable [11, 17, 64, 65]. Previous research demonstrated
a perivascular niche for Nestin-expressing GSCs
[18, 66]. However, immunohistochemical studies
have demonstrated expression of CD133 not only in
perivascular niches, but also in hypoxic regions [19, 20],
supporting the idea that GSCs may also populate hypoxic
microenvironments in GBM. Indeed, hypoxia and acidic
stress promote the GSC phenotype [19, 21-26].
Our findings provide evidence for the co-existence
of distinct GSC phenotypes in perivascular and hypoxic
niches of any given tumor. In our model (Figure 8), which
precisely mirrors our findings in GBM biospecimens,
Notchhi GSCs show a strong predilection for vascular
niches, likely due to the presence of Notch ligands on
endothelial cells. Notchhi GSCs are not merely passive
residents in perivascular microenvironments, but rather
actively help create them, by transdifferentiating into
pericytes. This finding is supported by recent literature
showing that NICD1 overexpression induces pericytic
differentiation in GBM [55]. We showed that the welldeveloped tumor vasculature in tumors initiated by Notchhi
cells produces adequate blood perfusion to prevent tumor
hypoxia, and that the relatively aerobic metabolism of
Notchhi GSCs is precisely tuned to this microenvironment.
Finally, we demonstrated that activation of Notch
signaling is sufficient for metabolic reprogramming of
tumor cells by suppressing anaerobic glycolysis.
Our model also shows that CD133hi GSCs populate
the tumor more diffusely, with reduced requirement for
perivascular localization. This observation is consistent
with previous demonstrations of CD133 immunoreactivity
in both perivascular and hypoxic niches in GBM [19, 20].
The DP population in our study may indeed reflect this
perivascular cell population that expresses CD133 and still
relies on Notch signaling. However, our findings strongly
suggest a hierarchical relationship between Notchhi and
CD133hi cells. We postulate that, as the tumor expands
and tumor cells move away from vessels, Notchhi GSCs
generate DP and, subsequently, CD133hi lineages. We
found that CD133hi GSCs have limited differentiation
capacity and do not generate Notchhi cells or pericytes.
Tumors initiated by CD133hi cells are hypoxic due to
underdeveloped vasculature and reduced blood perfusion.
To adapt to this hypoxic microenvironment, CD133hi
GSCs specifically entrain a defined transcriptional network
that allows them to bias glucose metabolism to anaerobic
glycolysis rather than oxidative phosphorylation. While
CD133hi cells thrive in hypoxic conditions, Notchhi GSCs
undergo apoptosis, suggesting that their preference for
aerobic glucose metabolism mandates a perivascular
niche. Therefore, we propose that Notchhi and CD133hi
GSCs support tumor growth via two parallel mechanisms.
We showed that canonical Notch signaling
suppresses anaerobic glycolysis and confers vulnerability
to hypoxia. This is a novel function of Notch signaling
www.impactjournals.com/oncotarget

in GBM. Previous reports suggested that hypoxia is
associated with induction of several components of the
Notch pathway [24, 67]. We propose that this induction
is compensatory, in order to boost vascularization and
tissue oxygenation by Notchhi lineages. Nonetheless, our
data indicate a critical window of vulnerability during
hypoxia: Notchhi cells, which drive angiogenesis, are prone
to apoptosis due to inability to rely on anaerobic glucose
metabolism. Future experiments will need to determine
the reason this inherent antithesis characterizes Notch
signaling in GBM. One interesting possibility is that
the broad differentiation potential of Notchhi cells may
mandate aerobic metabolism.
Previous reports suggested that blockade of Notch
signaling depletes CD133hi cells [6, 33, 50]. However,
GSC sensitivity to blockers of Notch signaling is inversely
related to the level of cell surface CD133 expression
[51] and GBM cultures can expand in the presence of
γ-secretase inhibitors [68], suggesting Notch-independent
growth. Our model reconciles these discrepancies. While
Notchhi and CD133hi cells represent largely distinct
populations, we found that multipotent Notchhi cells
generate CD133hi lineages. The reduction in CD133hi cell
counts after Notch inhibition can, therefore, be explained
by depletion of the Notchhi to CD133hi differentiation
program. The recent clinical trial with a Notch inhibitor
demonstrated that tumors do recur despite Notch inhibition
[50]. We explain this as tumor propagation by CD133hi
cells, which are resistant to Notch blockade, as we and
Tanaka et al. [51] showed, and are already present at the
time of Notch inhibition.
Our findings cannot rule out the possibility of GSC
types other than Notchhi and CD133hi cells. For example,
our xenograft studies demonstrate that the DN population
does contain cells with tumor-initiating properties.
However, the smaller size of tumors initiated by DN cells
suggests a relatively low frequency of tumor-initiating
cells in this population.
Overall, our observations suggest tumor progression
in GBM is mediated by distinct GSCs populating vascular
and hypoxic niches. This heterogeneity provides an escape
mechanism for tumors treated with agents targeting a
single subtype but not both. For example, most patients
with GBM are resistant to anti-angiogenic therapies [2, 3,
69], likely due to selective kill of hypoxia-vulnerable cells
but tumor progression by cells that tolerate hypoxia [70].
Likewise, Notch inhibitors failed to prevent recurrence
[50], likely due to tumor lineages that do not depend on
the Notch pathway. Our model provides a mechanistic
understanding of both hypoxia-vulnerable (Notchhi)
and -resistant (CD133hi) GSC lineages. We propose
that future treatments will need to take into account this
heterogeneity, in order to improve patient outcomes.
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MATERIALS AND METHODS

defined as above. Three regions of interest (ROIs) were
defined for each image: promixal (0-15 μm from blood
vessels), distal (15-30 μm) and outer ( > 15 μm). GFP and
CD133 immunofluorescence was identified in each ROI.
The estimate of number of cells/ROI was calculated by
dividing the total GFP+ or CD133hi positive area by the
estimated average area of a cell (86.2 ± 9.7 µm2).

GBM biospecimen immunostaining for NICD1
Chromogenic Immunohistochemistry was performed
on formalin-fixed paraffin-embedded GBM tissue on a
Discovery XT platform (Ventana Medical Systems Inc.,
Tucson, AZ) using Ventana’s reagents, unless otherwise
noted. Six µm-thick sections were deparaffinized in xylene
and rehydrated through graded alcohols. Heat induced
antigen retrieval was performed in a BioCare Decloaking
Chamber in Tris-EDTA buffer for 20 minutes at 120oC and
17 PSI and incubated in 3% hydrogen peroxide for 4 min.
NICD1 antibody (1:100, Abcam, ab8925) was incubated
for 3 hours and detected using anti-rabbit horseradish
peroxidase multimer (OmniMap). Immune complexes
were visualized with 3,3’-diaminobenzidene (DAB) and
enhanced with copper sulfate (ChromoMap). Slides were
counterstained with hematoxylin, dehydrated and mounted
with permanent media.

Plasmids and constructs
NotchLenti reporter construct (pGreenFire) was
obtained from Systems Biosciences. The NotchLentimCherry reporter was constructed by swapping
the copGFP cassette with a mCherry cassette. The
NotchLineage system was generated using two lentiviral
constructs. The CreERT2 cassette and reporter construct
were kind gifts of Dr. Philippe Ravassard (INSERM,
France) [56]. CreERT2 was subcloned into the pGreenFire
construct in place of copGFP. A loxP-DsRed-STOP-loxPGFP lentiviral construct was used as the reporter for the
NotchLineage experiments (Supplementary Figure 7ci).
The lentiviral vector overexpressing NICD1 was generated
by cloning the NICD coding frame into pLVX-mCherryN1
(Clontech), into the puromycin cassette. NICD1 plasmid
which the subcloning was done was a kind gift of Dr.
Iannis Aifantis (NYU School of Medicine).

Primary tumor cultures
We followed a protocol approved by NYU
Langone Medical Center’s Institutional Review Board
(IRB) to procure fresh tumor tissue from consented
patients undergoing surgery for resection of GBM
(IRB# S12-01130). Primary human GBM cultures were
obtained as previously described [44, 46, 47]. Four
primary GBM cultures were used for the experiments
described here (GBML8, GBML20 and GBML33 were
used for NotchLenti experiments; GBML8, GBML20
and GBML61 were used for NICD-OE experiments)
(Supplementary Figure 1). DNA was extracted from
formalin-fixed paraffin embedded tissue and analyzed
using Infinium 450k DNA methylation array, as described
previously [47]. Tumors were classified according to their
methylation profiles [48].

Lentivirus production
Lentiviruses were generated in Lenti-X 293
HEK (Clontech) producer cells after lipofection
(Lipofectamine-2000, Life Technologies) with a
combination of: transfer plasmid, encoding the viral
genome; packaging plasmids (ViraPower Lentiviral
expression systems, Life Technologies), encoding
structural and enzymatic components of viral particles;
and envelope plasmids, encoding viral envelope proteins.
Lenti-X 293 HEK cells were cultured in Dulbecco’s
Minimal Essential Media (DMEM, Life Technologies)
supplemented with 10% FBS and non-essential amino
acids. Lentiviral supernatant was collected at day 2 and 3
after transfection, filtered (0.45 μm filter) and concentrated
with ultracentrifugation (28,000g for 3 hours at 4°C)
using a 4% sucrose/PBS cushion. After centrifugation,
the supernatant was discarded and viral pellets were
resuspended in Opti-MEM medium, aliquoted and stored
at -80°C. Titers were determined by flow cytometry or
qPCR-based assays (ABM).

Quantification of distance of cells from the
vasculature
ImageJ was used for estimating the distance
of tumor cells from the vasculature. Three μm-thick
optical sections from confocal z-stacks were obtained.
Vasculature was identified using CD105 immunostaining.
To obtain the number of vessels and vascular area, images
were thresholded (Otsu Thresholding, ImageJ) using
tissue not treated with primary antibody as negative
control, and converted to binary format. Vessels > 10
μm in length were counted. An average of 4 fields were
calculated for each animal. In order to quantify the
distance of cells from the vasculature, blood vessels were
www.impactjournals.com/oncotarget

Viral transduction
Primary GBM tumorsphere cultures were
dissociated with Accutase (Innovative Cell Technologies).
Cells (300 cells/μl) were incubated at 37°C overnight
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with lentivirus at a multiplicity of infection (MOI) of 5.
Protamine sulfate (4 μg/mL) was added to facilitate viral
transduction. Three days after transduction, transduced
cells were selected with appropriate antibiotics. In the case
of NotchLenti, selection with 1 μg/mL puromycin (Life
Technologies) was performed for 5-7 days.

induction and
performed.

staining

was

Flow cytometry
For flow cytometric analysis, cells were dissociated
with Accutase. CD133 staining was performed with
fluorophore-conjugated AC133 antibody (Miltenyi), which
recognizes the CD133/1 epitope. The LSRII analyzer (BD
Biosciences) was used for flow cytometric measurements.
For fluorescence-assisted cell sorting (FACS), a FACSAria
cell sorter (BD Biosciences) was used with assistance
from the NYU Langone Medical Center’s Cytometry and
Cell Sorting Core Facility staff.

Animals and stereotactic injections into mouse
brain
Mice were housed within NYU Langone Medical
Center’s Animal Facilities. All procedures were performed
according to our IACUC-approved protocol (IACUC#
120310-03). 6-8 week old NOD.SCID male mice
(Jackson Laboratory, NOD.CB17-Prkdcscid/J, 001303)
were anesthetized with i.p. injection of ketamine/xylazine
(10 mg/kg and 100 mg/kg, respectively). They were then
mounted on a stereotactic frame (Harvard Apparatus).
A midline skin incision was made. A high-speed drill
was used to drill a small hole in the calvaria 2 mm off
the midline and 2 mm anterior to coronal suture. Five μl
of a suspension of human GBM cells (100,000 cells/μl,
unless otherwise noted) were injected through a Hamilton
syringe (1 μl/min, Harvard apparatus, needle pump) into
the frontal lobe through the drilled hole. The injection
needle was left in place for an additional 5 minutes after
the injection was completed to prevent backflow. The
skin incision was sutured and animals were monitored
throughout the recovery period.

qRT-PCR expression analysis
Lysates and cDNA were prepared from 10,000
FACS-isolated cells using TaqMan Gene expression Cellsto-Ct kit using the manufacturer’s protocol (Ambion, Life
Technologies). Taqman gene expression probes against
PROM1 (CD133), NOTCH1, NOTCH2, HES1, HES5,
HEY1, DLL1, JAG1 AND JAG2 (Supplementary Table
11a) (Ambion, Life Technologies) were used to analyze
changes in gene expression with qRT-PCR (Applied
Biosystems, StepOne Real-time PCR System). Fold
changes in expression were calculated using the ΔΔCt
method. The HPRT1 gene was used to normalize results.

Genomic DNA isolation and genomic PCR

Small animal MRI

Genomic DNA was isolated from 50,000 FACSisolated cells using the DNeasy Blood and Tissue Kit
(Qiagen). Genomic DNA (100 ng) was used in a nestedPCR to amplify copGFP DNA with the GoTaq DNA
Polymerase kit (Promega) (Supplementary Table 11b).
pGreenFire plasmid DNA was used as a positive control.
PCR products were analyzed with 1.2% agarose gel
electrophoresis.

Tumor formation was analyzed 1.5 months (unless
otherwise noted) after injection of tumor cells into the
brains of NOD.SCID mice. An MRI device bearing a
7-Tesla horizontal bore Bruker magnet (ID = 300mm with
zero boil off technology) in the Small Animal Imaging
Core Facility at NYU School of Medicine was used for
imaging. Prior to imaging animals were anesthetized with
isoflurane gas. Stacked images were processed using
ImageJ software. Tumor volumes were calculated with
Amira Software.

Immunofluorescence staining and microscopic
analysis

Lineage tracing

When the experimental end-point was reached,
animals were anesthetized with Ketamine/Xylazine (10
mg/kg and 100 mg/kg, respectively) and systemically
perfused with first Phosphate-buffered Saline (PBS)
and then 4% paraformaldehyde. Isolated brain tissue
was mounted in OCT (Tissue-Tek) and 30 μm-thick
frozen sections were obtained using a cryostat (Leica).
Sections were blocked with 10% (w/v) BSA (Sigma),
0.1% Triton X-100 (Sigma) in PBS for 2 hours at room
temperature. The primary antibodies and the dilutions used
for immunostaining are summarized in Supplementary

GBM cells were transduced with the lentiviral
NotchLineage system (Supplementary Figure 7ci).
FACS-isolated DsRed+ cells were infected with a second
lentivirus containing the driver construct. Transduced
cells were selected with puromycin (1 μg/ml) for 7 days.
Intracranial xenograft tumors were generated. Upon
confirmation of tumors with MRI, two pulses of i.p.
tamoxifen (150 mg/kg) were administered on sequential
days. Animals were sacrificed 1 month after tamoxifen
www.impactjournals.com/oncotarget
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Table 12. Staining was performed in blocking solution
for 18 hours at 4°C. Alexa488, Alexa555 and Alexa647 conjugated secondary antibodies were used for fluorescent
labeling (Life Technologies). Nuclear chromatin was
counterstained with DAPI (Sigma). Epifluorescence
microscopy was performed on an Eclipse E800 fluorescent
microscope (Nikon). For confocal imaging, 30 μm z-stacks
were obtained with an LSM700 confocal microscope
(Zeiss). Image analyses were performed on ImageJ and
Adobe Photoshop.
For apoptosis analysis, Click-iT Alexa Fluor 647
imaging assay (Life Technologies) was used according to
the manufacturer’s protocol.

GEO accession number GSE99180.

Western blotting
GBM cells were lysed in Lysis Buffer (150
mM NaCl, 50 mM Tris pH 7.4, 1 mM EDTA, 0.1%
Triton-X100, 10% glycerol) supplemented with complete
protease inhibitor cocktail (Roche). Lysates were
centrifuged to remove debris and the supernatant was
quantified using the Bradford assay. The supernatant
was separated on an SDS-PAGE gel and transferred to
a nitrocellulose membrane (Biorad). The membrane was
probed with the following primary antibodies: anti-Hif1α
(Bethyl Laboratories); and anti-β-Actin (Santa Cruz
Biotechnology). Signal was detected with appropriate
HRP-conjugated secondary antibodies (Life Technologies)
suited for chemiluminescence (Thermo Scientific).

RNA isolation, library preparation, RNAsequencing and bioinformatics
RNA was isolated from 30,000 FACS-isolated
GBM cells using mirRNeasy Micro RNA isolation kit
(Qiagen). RNA-Seq libraries were prepared using the
Epicentre (Illumina) TotalScript RNA-Seq kit, starting
from 5 ng of DNAse I-treated total RNA, and using oligo(dT) as the primer for cDNA synthesis. The libraries were
pooled equimolarly and run on a HiSeq 2500 sequencing
system, as paired 50 nucleotide reads. We sequenced 4
cell populations (CD133hi, Notchhi, DP and DN) from 2
patient samples (GBML8 in duplicates; and GBML20). A
total of two flow cells were used. GBML8 samples (4 cell
populations in duplicates) were run in one flow cell; and
GBML20 samples (4 cell populations) samples were run
in another. Sequencing results were de-multiplexed and
converted to FASTQ format using Illumina Bcl2FastQ
software. Paired-end reads were aligned to the human
genome (build hg19/GRCh37) using the splice-aware
STAR aligner [71]. PCR duplicates were removed
using the Picard toolkit (http://broadinstitute.github.io/
picard). HTSeq package was utilized to generate counts
for each gene based on how many aligned reads overlap
its exons [72]. On average we obtained 116,558,873 ±
10,631,963 reads. The lowest number of reads obtained
was 83,887,138 and the highest was 158,844,383. These
counts were then used to test for differential expression
using negative binomial generalized linear models
implemented by the DESeq2 R package [72]. For
cumulative data analysis, GBML8 biological duplicates
were first averaged. Then, that average was averaged with
GBML20 data.
Gene set enrichment analysis (GSEA [57], http://
software.broadinstitute.org/gsea/, Broad Institute) was
performed on complete transcriptomes from CD133hi and
Notchhi cells with genes pre-ranked by fold change, as
well as on differentially expressed genes. Gene Ontology
analysis with DAVID [62] (https://david.ncifcrf.gov, NIH)
was performed on differentially expressed genes. RNAseq and GSEA data and analyses are accessible through
www.impactjournals.com/oncotarget

24-hour hypoxia treatment
Cells were treated with hypoxic gas mixture (1% O2,
5%CO2, balanced with N2) for 24 hours at 37°C using a
hypoxia chamber (Stem Cell Technologies).

Lactate and intracellular pH measurements
Extracellular and intracellular lactate from cell
culture medium and cell lysates, respectively, was
measured with a colorimetric assay (Eton Bioscience). For
pH recordings, FACS-isolated GBM cells were plated onto
laminin-coated coverslips and left to settle for 1-2 hours
before recording. Coverslips with attached cells served as
the floor of a submersion chamber mounted on the stage
of an Olympus IX-73 inverted microscope equipped for
epifluorescence. The cells were loaded with pH-sensitive
fluorophore BCECF (2′,7′-bis-(2-carboxyethyl)-5-(and6)-carboxyfluorescein) by incubation with 2 μM of the
acetoxy-methylester (Life Technologies, CA) for 10 min
at room temperature. During the experiment the cells
were perfused at the rate of 2 ml/min with warmed (32°C)
standard bicarbonate-buffered saline containing (in mM):
124 NaCl, 26 NaHCO3, 3.0 KCl, 1.0 NaH2PO4, 2.0 CaCl2,
1.5 MgCl2, and 10 glucose. Solution was gassed with 95%
O2 and 5% CO2 and had a nominal pH of 7.4. A 75 W
xenon lamp and a monochromator provided alternate 490
and 440 nm fluorescence excitation. For each excitation
wavelength, the respective emissions above 535 nm
(F490 and F440, respectively) were collected via a 40x
oil-immersion objective and an intensified CCD camera.
Averaged fluorescence from regions of interest around
single cells was imaged using ImageMaster software
(Photon Technology International). The F490:F440
ratios were converted to pHi (intracellular pH) using the
nigericin single point technique, applying a HEPES64948
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buffered calibration solution (150 mM K+ and 3 μM
nigericin, pH 7.0) at the end of each experiment [20].
Data were referenced to a calibration curve previously
constructed using nigericin-150 mM K+ solutions buffered
with PIPES or HEPES over the pH range of 6.0-8.0.
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